1. Scrip
  2. >>R&D

R&D Reorg Helps Astellas Move Swiftly With Protein Degraders

KRAS G12D Asset Leads Pack

 
• By Lisa Takagi

In selecting targeted protein degradation as a new Primary Focus area within its R&D effort, Astellas has moved rapidly to develop a potential first-in-class KRAS G12D degrader candidate ASP3082, helped by a reorganization last year to develop a more agile research function. The Japanese firm sees very broad potential for TPDs beyond oncology in the longer term.

In the process of developing TPD candidates, restructured R&D organization since 2021 enabled agile decision making, says Astellas.
restructured R&D organization has helped agile decision-making, says Astellas • Source: Shutterstock

Astellas Pharma, Inc. chose to highlight its growing R&D activities in the hot area of targeted protein degradation (TPD) at its recent R&D Meeting, apparently becoming the first major Japanese pharma firm to disclose a strategic focus on the increasingly competitive field.

It has already developed several candidates including the potential first-in-class KRAS G12D degrader ASP3082, for which a Phase I trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.